Levi & Korsinsky Announces an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. (AMPH) Shareholders Who May Have Been Affected by Fraud
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) for potential violations of federal securities laws. This follows the FDA's issuance of a secondary complete response letter for Amphastar's generic teriparatide ANDA, AMP-015, after significant delays.
February 25, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after receiving a secondary CRL from the FDA for its generic teriparatide, AMP-015.
The investigation by Levi & Korsinsky and the FDA's secondary CRL for AMP-015 suggest potential legal and regulatory challenges for Amphastar. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100